Roth Capital raised the firm’s price target on Astera Labs (ALAB) to $275 from $225 and keeps a Buy rating on the shares. The company reported another solid revenue beat and raise in the quarter on the back of continued retimer revenue growth and ramping PCIe switch revenue contribution, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
Double your ALAB exposure with Tradr's LABXPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALAB:
- Quinn Bolton Lifts Astera Labs Price Target to $260 on Strong Product Momentum and Long-Term AI Growth Drivers
- Astera Labs Earns Buy Rating on Strong Q1 Results, Surging Scorpio AI Switch Demand, and Expanding Connectivity Portfolio
- Sean O’Loughlin Reiterates Hold on Astera, Lifts Price Target to $225 Amid Strong Near-Term Upside but Longer-Term Competitive Uncertainty
- Astera Labs’ Earnings Call Highlights Explosive AI Growth
- Astera Labs Inc options imply 11.1% move in share price post-earnings